Vitiligo

The COVID-19 pandemic has drawn attention to acne associated with the prolonged use of medical face masks and raised awareness about the need for adequate screening, training and treatment of the condition.

Vitiligo clinical experts discuss the role of maintenance therapy in preventing recurrence of vitiligo.

Drs. Woolery-Lloyd, King and Pandya discuss time to re-pigmentation of different areas in vitiligo.

Investigators identified a correlation between severity of kidney-urinary tract complications and the affected protein involved with intermediate junctional epidermolysis bullosa (JEB).

Despite their tendency to present with more severe psoriasis compared with other races and ethnicities, Asian patients receive significantly less time with a dermatologist.

Drs. Woolery-Lloyd, Rosmarin and Pandya discuss various treatment options for vitiligo and when and where they might use them.

Dr. Rosmarin and other panelists share their thoughts on how to treat different areas of the body and the role of tattoos.

Although sharing a common feature of male predominance, alopecia did not seem to occur more frequently in AS patients.

45% of study participants were either dissatisfied or very dissatisfied with their current medical treatment.

Dr. Pandya shares his conversations with patients about re-pigmentation of segmental and non-segmental vitiligo and treatment options that exist.

Drs. Pandya and King discuss challenges in re-pigmentation, including glabrous skin and areas that may not re-pigment.

Dr. Rosmarin provides an overview of models of re-pigmentation in vitiligo.

Drs. Rosmarin and King discuss the importance of shared-decision making and understanding of patient goals in managing vitiligo.

Dipeptidyl peptidase-4 inhibitors have been linked to cases of bullous pemphigoid across Japan, prompting investigators to suggest trying DPP-4i discontinuation followed by supportive care.

The novel topical skincare treatment Total Eye was effective in treating periorbital wrinkles, dryness, laxity, and dark circles in patients 35-65 years old.

With this decision, ruxolitinib cream has become the first treatment approved by the FDA for the repigmentation of skin in vitiligo.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Cohen speaks on combining sun protective measures, such as sunscreen, protective clothing, and antioxidant supplements.

Dr. Lal speaks to how different cultures and different geographical locations can influence UV protection methods, and how sunless tanners can be used to avoid overexposure to UV light outdoors or in tanning beds.

Dr. Craiglow speaks on the public perception of UV safety, how people can best avoid sunburn, and her own personal experience with melanoma and non-melanoma skin cancers.

The authors unanimously agreed that doctors should explain the potential benefits and negatives of the treatment and all centers should have a phototherapy protocol in place to address episodes of symptomatic erythema and other adverse events.

Dr. Harold Edington gives an overview of Australia's public health campaign regarding UV safety, as well as the lessons Americans can take away from these measures.

Drs. Pandya and King discuss patient’s visit and how providers can help set expectations about the disease course.

Dr. Woolery-Lloyd shares her approach to talking to patients about vitiligo.

Drs Woolery-Lloyd, King and Pandya share how vitiligo affects patients’ quality of life.

Drs Rosmarin, King, and Pandya give an overview of clinical presentation and classification of vitiligo.

Though a majority of the study population could not identify the condition, certain groups- such as Arab-speaking participants- had a basic knowledge of and positive attitude toward vitiligo.

Investigators suggest that health care providers have a “unique opportunity” to facilitate shared decision making and empower patients and caregivers by involving them in the practice of eczema care.

Drs Pandya discusses vitiligo pathophysiology, the role of genetic and environmental factors, and how to communicate with patients about it.

A vitiligo expert, Dr Amit Pandya, provides an overview of vitiligo.